Cara Therapeutics IncNASDAQ:CARANASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.3050
- TODAY'S CHANGE (%)0.0171 (5.9396%)
- Bid / Lots0.2830/ 100
- Ask / Lots0.3050/ 76
- Open / Previous Close0.2879 / 0.2879
- Day Range
- 52 Week Range
- Volume644,309
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CARA |
|---|---|---|
| 09:32 ET | 2422 | 0.2875 |
| 09:34 ET | 500 | 0.2875 |
| 09:39 ET | 1330 | 0.2893 |
| 09:41 ET | 2893 | 0.2832 |
| 09:43 ET | 17080 | 0.2899 |
| 09:54 ET | 1455 | 0.28001 |
| 09:59 ET | 398 | 0.284376 |
| 10:08 ET | 1095 | 0.2898 |
| 10:10 ET | 593 | 0.2898 |
| 10:15 ET | 1000 | 0.28775 |
| 10:19 ET | 390 | 0.282 |
| 10:21 ET | 100 | 0.2889 |
| 10:24 ET | 600 | 0.2894 |
| 10:26 ET | 359 | 0.2817 |
| 10:33 ET | 1414 | 0.282485 |
| 10:35 ET | 555 | 0.2898 |
| 10:39 ET | 400 | 0.2898 |
| 10:44 ET | 368 | 0.2898 |
| 10:48 ET | 100 | 0.282474 |
| 10:50 ET | 460 | 0.2861 |
| 10:53 ET | 6095 | 0.2899 |
| 10:55 ET | 13499 | 0.2825 |
| 11:00 ET | 333 | 0.2909 |
| 11:04 ET | 13244 | 0.2925 |
| 11:06 ET | 12817 | 0.2989 |
| 11:08 ET | 1000 | 0.299 |
| 11:15 ET | 1000 | 0.3 |
| 11:26 ET | 390 | 0.2999 |
| 11:27 ET | 300 | 0.2994 |
| 11:29 ET | 1200 | 0.2994 |
| 11:31 ET | 1334 | 0.292218 |
| 11:33 ET | 576 | 0.2994 |
| 11:36 ET | 1020 | 0.299 |
| 11:42 ET | 583 | 0.2989 |
| 11:45 ET | 460 | 0.2949 |
| 11:49 ET | 400 | 0.292 |
| 11:56 ET | 330 | 0.296925 |
| 11:58 ET | 310 | 0.296925 |
| 12:00 ET | 10148 | 0.2995 |
| 12:02 ET | 100 | 0.298213 |
| 12:07 ET | 150 | 0.291201 |
| 12:09 ET | 400 | 0.297425 |
| 12:12 ET | 1355 | 0.2995 |
| 12:14 ET | 300 | 0.2995 |
| 12:18 ET | 900 | 0.297925 |
| 12:25 ET | 3319 | 0.2932 |
| 12:30 ET | 400 | 0.299 |
| 12:38 ET | 363 | 0.2994 |
| 12:41 ET | 12206 | 0.2929 |
| 12:52 ET | 100 | 0.2961 |
| 12:54 ET | 628 | 0.2977 |
| 12:57 ET | 469163 | 0.308 |
| 12:59 ET | 18001 | 0.2956 |
| 01:08 ET | 2000 | 0.2956 |
| 01:19 ET | 339 | 0.29565 |
| 01:21 ET | 100 | 0.2931 |
| 01:24 ET | 600 | 0.2922 |
| 01:26 ET | 300 | 0.2922 |
| 01:33 ET | 300 | 0.2957 |
| 01:39 ET | 100 | 0.2957 |
| 01:51 ET | 700 | 0.292472 |
| 01:57 ET | 523 | 0.2992 |
| 02:02 ET | 600 | 0.2958 |
| 02:06 ET | 400 | 0.2992 |
| 02:09 ET | 400 | 0.2992 |
| 02:11 ET | 999 | 0.292468 |
| 02:13 ET | 1100 | 0.2958 |
| 02:15 ET | 337 | 0.2925 |
| 02:18 ET | 400 | 0.2992 |
| 02:26 ET | 829 | 0.2924 |
| 02:27 ET | 100 | 0.2933 |
| 02:33 ET | 414 | 0.2912 |
| 02:38 ET | 226 | 0.292065 |
| 02:49 ET | 600 | 0.297 |
| 02:58 ET | 600 | 0.294 |
| 03:05 ET | 100 | 0.2932 |
| 03:07 ET | 249 | 0.2975 |
| 03:09 ET | 305 | 0.2992 |
| 03:12 ET | 828 | 0.2932 |
| 03:14 ET | 500 | 0.2992 |
| 03:21 ET | 950 | 0.2992 |
| 03:27 ET | 1100 | 0.2989 |
| 03:32 ET | 600 | 0.299 |
| 03:34 ET | 600 | 0.2941 |
| 03:41 ET | 505 | 0.299 |
| 03:43 ET | 100 | 0.2973 |
| 03:50 ET | 335 | 0.2974 |
| 03:52 ET | 2718 | 0.2977 |
| 03:54 ET | 800 | 0.2977 |
| 03:56 ET | 2500 | 0.305 |
| 03:57 ET | 1300 | 0.305 |
| 03:59 ET | 6058 | 0.305 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Cara Therapeutics Inc | 15.8M | -0.1x | --- |
Turnstone Biologics Corp | 12.9M | -0.2x | --- |
SQZ Biotechnologies Co | 1.0M | 0.0x | --- |
Viaderma Inc | 6.7M | 0.0x | --- |
ImmuCell Corp | 28.3M | -6.8x | --- |
Eiger BioPharmaceuticals Inc | 12.6M | -0.2x | --- |
Company Information
Cara Therapeutics, Inc. is a development-stage biopharmaceutical company. The Company is focused on treatment paradigm to improve the lives of patients suffering from chronic pruritus. It is developing an oral formulation of difelikefalin, a selective, predominantly peripherally acting, non-scheduled Kappa opioid receptor agonist, for the treatment of chronic neuropathic pruritus associated with Notalgia Paresthetica (NP), a common, underdiagnosed neuropathy affecting the upper back. It is conducting Phase II/III Clinical Program in NP. The program is comprised of two studies - KOURAGE 1 and KOURAGE 2, which are double-blind, placebo-controlled, eight-week studies with patients allowed to roll-over into open-label 52-week extensions. It has developed an IV formulation of difelikefalin, for the treatment of moderate-to-severe pruritus associated with advanced chronic kidney disease in adults undergoing hemodialysis. The IV formulation is out-licensed worldwide.
Contact Information
- Headquarters
- 400 Atlantic Street, Suite 500STAMFORD, CT, United States 06901
- Phone
- 203-406-3700
- Fax
- 203-567-1510
Executives
- Independent Chairman of the Board
- Martin Vogelbaum
- President, Chief Executive Officer, Director
- Christopher Posner
- Chief Financial Officer
- Ryan Maynard
- Chief Compliance Officer, General Counsel, Secretary
- Scott Terrillion
- Director
- Helen Boudreau
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $15.8M |
|---|---|
Revenue (TTM) | $11.0M |
Shares Outstanding | 54.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.70 |
EPS | $-2.04 |
Book Value | $1.05 |
P/E Ratio | -0.1x |
Price/Sales (TTM) | 1.4 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -1,000.06% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
